Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Merck & Co., Inc. (MRK), Akamai Technologies, Inc. (AKAM), Cyberonics, Inc. (CYBX): Next Leaders in Technology and Health Care

In an unusual divergence, stocks belonging to the defensive health care and cyclical technology spaces delivered some of the best responses to earnings last quarter .  Does this sector diversity indicate bullish omens in the months ahead? It’s certainly a good sign, but what are the opportunities in these high-performing sectors?

Merck & Co., Inc. (NYSE:MRK)

Akamai Technologies, Inc. (NASDAQ:AKAM) is pushing new 52-week highs. In its most recent quarter, the company reported revenues of $378 million, a 14% year-over-year increase with a 25% gain in net income . Better still, its fast-growing security solutions division generated nearly half of its total revenues: During Q4, the segment saw five times growth on the prior year quarter, and subsequent first and second quarters delivered growth of 17%  and 19%, respectively, in year-on-year comparisons, primarily driven by up-sales to existing clients. The company has been hiring sales staff to attract new customers, but admitted that it would take four or five quarters to get the full benefits of these hires.

In light of this, a repeat of the 7% sequential rise in security revenue from the current quarter for next quarter would add $12 million, which is the total revenue gain projected by analysts for next quarter,  excluding any gain coming from its content acceleration or services divisions. There is a good chance it could deliver another beat next quarter.

Health care
Behemoth Merck & Co., Inc. (NYSE:MRK) may be the sleeper pick of the sector — if such a large stock could be considered a “sleeper.”

Last year, the company lost its patent on Singulair, its second-biggest-selling drug in its pipeline after Januvia . In the most recent quarter, Singulair saw a 80% drop in sales compared to last year, which amounted to a $1 billion loss . Despite this, overall pharmaceutical sales were down just 12% for the quarter

The more modest loss in gross pharmaceutical sales was assisted by double-digit, year-on-year quarterly growth in Merck & Co., Inc. (NYSE:MRK)’s second-tier product line: Janumet, Gardasil, NuvaRing, Nasonex, and Simponi . Collectively, these drugs delivered $1.47 billion quarterly sales.

Singulair sales, while a far cry from their peak, can still generate some revenue for Merck & Co., Inc. (NYSE:MRK); Zocor and Fosamax once delivered peak annual sales of $4.4 billion and $3 billion, respectively , but these two drugs still together deliver more than $1 billion in sales despite patents expiring over five years ago.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.